DEFA14A 1 tv490063_defa14a.htm DEFA14A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant x

Filed by a Party other than the Registrant ¨

Check the appropriate box:

¨ | Preliminary Proxy Statement

¨ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

¨ | Definitive Proxy Statement

x | Definitive Additional Materials

¨ | Soliciting Material Pursuant to §240.14a-12

Protalix BioTherapeutics, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

x | No fee required.

¨ | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

| 1) | Title of each class of securities to which transaction applies:
| 2) | Aggregate number of securities to which transaction applies:
| 3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set
|  | forth the amount on which the filing fee is calculated and state how it was determined):
| 4) | Proposed maximum aggregate value of transaction:
| 5) | Total fee paid:

¨ | Fee paid previously with preliminary materials.

¨ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing:

| 1) | Amount Previously Paid:
| 2) | Form, Schedule or Registration Statement No:
| 3) | Filing Party:
| 4) | Date Filed:

An Important Message to Stockholders of Protalix Biotherapeutics The 2018 Annual Meeting of Stockholders of Protalix Biotherapeutics, Inc. will be held on April 15, 2018. Why is this important to you? The Board of Directors of Protalix Biotherapeutics believes that it is in the best interest of our stockholders to increase the number of authorized shares of common stock available for future issuance (Proposal #4). As an investor you have the opportunity to vote on this important matter that will help advance opportunities for the company. Your support of proposal 4 will permit the board to increase the number of authorized shares of our common stock from 250 Million to 350 Million. Without the recommended increase in shares, the Protalix management team will not have the flexibility needed to raise the capital required to expand our pioneering work in biotherapeutics. What do you need to do: Vote your shares now without delay. To ensure your “Yes” on Proposal 4, you can speak to a Shareholder Advisor by calling Toll Free: 1 (833) 501-4837

Your Shareholder vote will support continued Biotherapeutic Innovation… Protalix Biotherapeutics is developing an innovative product pipeline using its proprietary ProCellEx® protein expression system which is focused on products that we believe offer a clear competitive advantage over existing treatments. Keep Our Work Going By authorizing the proposed increase in authorized common stock, you will allow the Board to raise the capital necessary to continue our clinical research efforts. Failure to approve the proposed amendment to our Certificate of Incorporation will seriously restrict our ability to manage our capital needs and will be detrimental to your interests in our company. What Others are Saying Two leading independent shareholder advisory firms: Institutional Shareholder Services - ISS and Glass Lewis, both recommend stockholders support for the proposal to increase the number of shares of Protalix’s common stock. The requested increase is reasonable and there are no substantial concerns about the company’s past use of shares.” —ISS Vote is Needed Today. To support the Board’s recommendation and vote “Yes” on Proposal 4, call toll-free: 1 (833) 501-4837 to speak to a Shareholder Advisor.